Nachum Rosman Net Worth

The estimated Net Worth of Nachum Rosman is at least $997 Thousand dollars as of 24 February 2014. Nachum Rosman owns over 45,000 units of Pluri Inc stock worth over $222,964 and over the last 17 years Nachum sold PSTI stock worth over $774,338.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Nachum Rosman PSTI stock SEC Form 4 insiders trading

Nachum has made over 4 trades of the Pluri Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently Nachum sold 45,000 units of PSTI stock worth $180,000 on 24 February 2014.

The largest trade Nachum's ever made was selling 67,244 units of Pluri Inc stock on 8 November 2013 worth over $219,888. On average, Nachum trades about 9,193 units every 26 days since 2007. As of 24 February 2014 Nachum still owns at least 222,964 units of Pluri Inc stock.

You can see the complete history of Nachum Rosman stock trades at the bottom of the page.

What's Nachum Rosman's mailing address?

Nachum's mailing address filed with the SEC is 7 FINESTEIN ST., , TEL-AVIV, L3, 69123.

Insiders trading at Pluri Inc

Over the last 17 years, insiders at Pluri Inc have traded over $7,081,854 worth of Pluri Inc stock and bought 2,345,914 units worth $14,327,834 . The most active insiders traders include Wolf Capital Limited Part..., Zami Aberman, and Israel Ben Yoram. On average, Pluri Inc executives and independent directors trade stock every 64 days with the average trade being worth of $54,123. The most recent stock trade was executed by Zami Aberman on 10 February 2022, trading 80,616 units of PSTI stock currently worth $145,109.

What does Pluri Inc do?

Pluristem Therapeutics Inc. is a leading regenerative medicine company developing novel placenta-based cell therapy product candidates. The Company has reported robust clinical trial data in multiple indications for its patented PLX cell product candidates and is currently conducting late-stage clinical trials in several indications. PLX cell product candidates are believed to release a range of therapeutic proteins in response to inflammation, muscle trauma, hematological disorders and radiation damage. The cells are grown using the Company's proprietary three-dimensional expansion technology and can be administered to patients off- the-shelf, without tissue matching. Pluristem has a strong intellectual property position; a

Complete history of Nachum Rosman stock trades at Pluri Inc

Pluri Inc executives and stock owners

Pluri Inc executives and other stock owners filed with the SEC include:

• Yaacov Yanay,
  Pres, CEO & Director
• Zalman Aberman,
  Executive Chairman of the Board
• Yaky Yanay,
  President, Chief Executive Officer, Director
• Chen Franco-Yehuda,
  Chief Financial Officer, Treasurer, Secretary
• Dana Rubin,
  Director of Investor Relations
• Moria Kwiat,
  Independent Director
• Mark Germain,
  Independent Director
• Isaac Braun,
  Independent Director
• Doron Shorrer,
  Lead Independent Director
• Dr. Nitsan Halevy M.D.,
  Chief Medical Officer
• Efrat Livne-Hadass,
  VP of HR
• Lior Raviv,
  Chief Technology Officer
• Israel Ben Yoram,
  Director
• Nachum Rosman,
  Director
• Hava Meretzki,
  Director
• Erez Egozi,
  Chief Financial Officer
• Shai Pines,
  Director
• Boaz Gur Lavie,
  CFO
• Wolf Capital Limited Part...,
  10% owner
• Maital Shemesh Rasmussen,
  Director
• Rami Avraham Levi,
  Director
• Pinhas Doron Birger,
  Director
• Varda Shalev,
  Director
• Zami Aberman,
  Director